More accurate, predictive biomarker analysis may assist in the selection of effective combinatorial immunotherapy treatments for patients. Additionally, the complexity of both the tumor and tumor microenvironment suggests a comprehensive approach is needed for robust characterization of the cancer ecosystem. The ImmunoID NeXT™ platform investigates key aspects of immuno-oncology; from elucidating mechanisms of tumor escape and detecting neoantigens, to identifying novel biomarker signatures and characterizing the immune repertoire. This presentation will focus on one of the current challenges facing investigators in immuno-oncological translational research: analysis of complex data.
